ASHLEIGH FURLONG writes: A massive study has shown that about 85% of patients on antiretrovirals had got the virus down to acceptable levels. Those who had higher levels of the virus in their blood tended to be male and/or patients who were children or adolescents at the start of antiretroviral treatment.
Dr Dvora Joseph Davey from BroadReach Healthcare and the University of Cape Town described a study that looked at the factors associated with unsuppressed viral load in patients with HIV and on the “first line” of antiretroviral treatment (ART) in South Africa.
An unsuppressed viral load is when a patient is on ART but the treatment doesn’t bring the levels of HIV down to an acceptable level. This means they are more likely to die at a younger age and can pass on the virus to others more easily. First line treatment refers to the medicines that a patient is put onto first. If the treatment doesn’t work they may need to be put onto what is called “second line treatment”, which consists of a different set of medicines.
The study looked at all patients’ files who were on “first line treatment” for more than six months between January 2004 and were still on treatment by April 2016.
There were 244,370 patients in the study, with only 15% of them (37,487) being virally unsuppressed. The patients in the study were from 271 public health facilities in four different provinces. The most recent viral load result had to be unsuppressed for the patient to be classified as such.
The fact that 85% of these patients were virally suppressed is good as it is close to the national target of 90%.
Joseph Davey also found that patients with a low CD4 count (a measure of the strength of the immune system) at the start of treatment and those on TB treatment had higher odds of being virally unsuppressed. An additional factor increasing the odds of an unsuppressed viral load was being on treatment for either between six months and a year or over five years.
Joseph Davey called for a re-evaluation of policies and guidelines on the initiation of treatment in adolescents, children and men. She also said that there needs to be specific interventions for patients identified as at high-risk of having unsuppressed viral loads.
One example was changing adherence counselling and targeting resistance testing to make sure that those who acquired drug resistance are on the correct treatment regimen.
She said that a limitation of the study was that it was cross-sectional, meaning that it only looked at a specific point in time. She also said that 25% of all the possible patients they could have studied did not have a viral load in their file, meaning that the study could have underestimated the real proportion of patients on ART with an unsuppressed viral load.